Taru E. Muranen

This study identifies a metabolic-epigenetic mechanism linking leucine catabolism to glycolysis that drives resistance to CDK4/6 inhibitors in ER+ breast cancer.

This study identifies BRD2 as a co-targetable vulnerability with PI3K/AKT inhibitors in breast cancer, showing that BRD2 phosphorylation is required for chromatin binding and that targeting BRD2 enhances drug efficacy.

The paper introduces an image analysis pipeline to quantify spatial biomarker distributions in stroma-rich tumors using open-source tools and custom scripts.

This study shows that integrin-β4 upregulation suppresses ovarian cancer cell proliferation and protects cells from cisplatin, suggesting a role in chemoresistance.

This study identifies NDRG1 as a DNA repair protein that links pancreatic cancer stroma to chemoresistance by enhancing DNA damage repair through R-loop resolution.

This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.

This study shows that SARS-CoV-2 variants differ in syncytia formation, which affects host chromatin accessibility, cellular senescence, and inflammation via TP53.

The paper compiles protein response data from cancer cell lines to drug perturbations, showing improved drug sensitivity prediction and building a protein-drug connectivity map with an accessible data portal.